VK2735
InvestigationalA dual GLP-1/GIP receptor agonist from Viking Therapeutics with both subcutaneous and oral formulations. Phase 2 VENTURE trial showed 14.7% weight loss at 13 weeks (SC) and 12.2% (oral). Phase 3 VANQUISH-1 enrolled 4,500 patients.
Viking 2735
11 human studies
- Preclinical
- 8%
- Human research
- 92%
Based on 12 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The mechanisms of VK2735 are based on its dual GLP-1/GIP receptor agonism, a well-characterized pharmacological approach validated by tirzepatide approval.
How It Works (Simplified)
VK2735 activates two complementary hormone pathways for enhanced metabolic effects:
Binds GLP-1 receptors in brain and gut, reducing appetite, slowing gastric emptying, and enhancing glucose-dependent insulin release.
Activates GIP receptors on fat cells and pancreas, amplifying metabolic effects and potentially improving adipose tissue function.
Combined activation produces greater weight loss than either pathway alone, as demonstrated by tirzepatide vs semaglutide comparisons.
VK2735 oral formulation achieves systemic absorption without food restrictions, unlike oral semaglutide which requires fasting.
Key Research: VENTURE Phase 2 (2024) demonstrated 14.7% weight loss at 13 weeks with no plateau, suggesting continued efficacy with longer treatment.
Important Limitations
- Phase 3 data (VANQUISH-1) not yet available; efficacy based on Phase 2
- Long-term safety beyond 13 weeks not established in published data
- NOT commercially available - investigational drug only
- Comparison to approved agents (tirzepatide, semaglutide) requires Phase 3 results
Initial dose titration phase. GI side effects (nausea, diarrhea) most common during this period but typically mild-moderate. Early appetite suppression begins.
NCT06068946Continued weight loss with dose escalation. VENTURE data showed progressive weight reduction without plateau through week 13.
NCT06068946Phase 2 endpoint. 14.7% weight loss achieved at highest SC dose. Weight loss curves still declining, suggesting further reduction possible with longer treatment.
NCT06068946Phase 3 duration. VANQUISH-1 will evaluate 78-week efficacy and safety.
NCT07104500Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
BPC-157
CautionBoth affect GI function. VK2735 slows gastric emptying while BPC-157 is gastroprotective. Monitor GI symptoms if combined.
Tirzepatide
AvoidSame mechanism of action (dual GLP-1/GIP agonism). Concurrent use would be duplicative with increased risk of adverse effects. No clinical rationale for combination.
Semaglutide
AvoidOverlapping GLP-1 receptor agonism. Concurrent use would increase risk of GI adverse effects and hypoglycemia without additional benefit.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare VK2735
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191
AOD-9604 is a modified human-growth-hormone fragment investigated for obesity and fat metabolism. Its obesity development program did not establish efficacy, and current regulatory sources identify major safety and quality gaps for unapproved or compounded products.
Cagrilintide
AM833 · NN9838
Investigational long-acting amylin analogue. REDEFINE 1 included a Phase 3 cagrilintide-only arm; Novo reports 11.8% mean weight loss versus 2.3% with placebo at 68 weeks using an on-treatment estimand. Dedicated RENEW Phase 3 monotherapy trials have started. Cagrilintide is also a CagriSema component.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
Investigational fixed-dose cagrilintide plus semaglutide combination. Novo filed a US obesity NDA in December 2025. Its sponsor-reported REDEFINE 4 head-to-head trial missed non-inferiority versus tirzepatide; September 2026 REIMAGINE 5 and REDEFINE 9 toplines address different populations and doses. A filing and positive toplines are not FDA approval.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Compared With
10 comparisonsConditions Studied
2 entries- VK2735 for Obesity VK2735 is in Phase 3 development for obesity treatment. VENTURE Phase 2 demonstrated 14.7% weight loss at 13 weeks with subcutaneo…
- VK2735 for Type 2 Diabetes The VANQUISH-2 Phase 3 trial is studying patients with type 2 diabetes who are obese or overweight. The dual GLP-1/GIP mechanism i…